Study of TEV-50717 for the Treatment of Tourette Syndrome in Children and Adolescents
- Study Title
- Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
- Teva Identifier
- TV50717-CNS-30046 | 2016-000622-19
- ClinicalTrials.gov Identifier
- NCT03452943
- Study Status
- Completed
- Trial Condition(s)
- Tourette Syndrome
- Interventions
- Drug: TEV-50717 | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child
- Age Range
- 6 Years to 16 Years
- Trial Duration
- February 5, 2018 - November 12, 2019
- Phase
- Phase 2/3
